Last update 30 Mar 2025

Maridebart Cafraglutide

Overview

Basic Info

Drug Type
Peptide-Antibody Conjugates(PACs)
Synonyms
Anti-GIPR Antibody (Amgen), MariTide, AMG-133
+ [1]
Action
antagonists, agonists
Mechanism
GIPR antagonists(Gastric inhibitory polypeptide receptor antagonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3
Puerto Rico
12 Mar 2025
Diabetes Mellitus, Type 2Phase 2
United States
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Japan
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Australia
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Canada
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Czechia
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Germany
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Hong Kong
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Hungary
18 Jan 2023
Diabetes Mellitus, Type 2Phase 2
Poland
18 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
34
(Japanese Participants: AMG 133 Low Dose)
ygunhztxok(dyauejhfnr) = ktntkqlnof ucntpcdscm (mhcplczsvw, 57.3)
-
25 Mar 2025
(Japanese Participants: AMG 133 Medium Dose)
ygunhztxok(dyauejhfnr) = nhgdwzwdhz ucntpcdscm (mhcplczsvw, 24.1)
Phase 2
592
AMG 133 420 mg
(Without Type 2 Diabetes)
rdcevmqzyw(mrhbiateub) = Without Type 2 Diabetes: MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau; With Type 2 Diabetes: MariTide Delivered an Impressive up to ~17% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau cxamqjxhjf (ttbzdnxbyk )
Positive
26 Nov 2024
Placebo
(Without Type 2 Diabetes)
Phase 1
75
wabhzrarsv(eeocdrsfge) = amxxlaalzb mthhmwrlmn (dovtxqnjil )
Positive
07 Nov 2022
Placebo
wabhzrarsv(eeocdrsfge) = xihcxbjtdx mthhmwrlmn (dovtxqnjil )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free